相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib
P. A. Ascierto et al.
ANNALS OF ONCOLOGY (2020)
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma
S. Ugurel et al.
ANNALS OF ONCOLOGY (2020)
KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the β-catenin/STT3 signaling pathway
Zhiyan Ruan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
Paula Gonzalez-Ericsson et al.
JOURNAL OF PATHOLOGY (2020)
MicroRNA-519 inhibits hypoxia-induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD-L1
Kate Nong et al.
ONCOLOGY LETTERS (2020)
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells
Jason B. Williams et al.
NATURE COMMUNICATIONS (2020)
Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
Marine Cordonnier et al.
JOURNAL OF EXTRACELLULAR VESICLES (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
Jenny H. Lee et al.
NATURE COMMUNICATIONS (2020)
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy
Jiyong Liang et al.
CANCER IMMUNOLOGY RESEARCH (2020)
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
Brian Diskin et al.
NATURE IMMUNOLOGY (2020)
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer
G. Lamberti et al.
ANNALS OF ONCOLOGY (2020)
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai et al.
NATURE IMMUNOLOGY (2020)
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas
Eleni Anastasiadou et al.
LEUKEMIA (2019)
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma
Fajun Qu et al.
JOURNAL OF DRUG TARGETING (2019)
miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint
Duolu Li et al.
EXPERIMENTAL CELL RESEARCH (2019)
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
Yoko Tsukita et al.
MOLECULAR CANCER (2019)
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C. Miller et al.
NATURE IMMUNOLOGY (2019)
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang et al.
NATURE MEDICINE (2019)
MiR-873/PD-L1 axis regulates the stemness of breast cancer cells
Lanlan Gao et al.
EBIOMEDICINE (2019)
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis
Yibo Fan et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
Audrey Lequeux et al.
CANCER LETTERS (2019)
Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma
Dong-Ping Chen et al.
JOURNAL OF HEPATOLOGY (2019)
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Piao Li et al.
JOURNAL OF IMMUNOLOGY (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Abdullah Al Emran et al.
TRENDS IN IMMUNOLOGY (2019)
Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p
Wen-Yang Zhou et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Li-Chuan Chan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Clonal replacement of tumor-specific T cells following PD-1 blockade
Kathryn E. Yost et al.
NATURE MEDICINE (2019)
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
Ping-Chih Hsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer
Koji Teramoto et al.
LUNG CANCER (2019)
miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1
Wei Jiang et al.
ONCOTARGETS AND THERAPY (2019)
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Kathleen M. Mahoney et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
Hoibin Jeong et al.
CANCER RESEARCH (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Interferon-Gamma Paradox in Cancer
M. Raza Zaidi
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2019)
A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2
Yuanpei Xu et al.
CELL REPORTS (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam et al.
ANNALS OF ONCOLOGY (2018)
Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1
Bai He et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1
Chia-Wei Li et al.
CANCER CELL (2018)
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells
Yang Wang et al.
CELL CYCLE (2018)
MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC
Wei-Bin Xie et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint
Zhen Tao et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma
Ping-Chih Hsu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer
Dongfang Tang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer
Peixin Dong et al.
ONCOGENE (2018)
miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway
Jun Wan et al.
ONCOLOGY REPORTS (2018)
Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16
Ning Wang et al.
ONCOLOGY RESEARCH (2018)
Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion
Cheng Sun et al.
NATURE COMMUNICATIONS (2018)
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu et al.
NATURE COMMUNICATIONS (2018)
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Catherine S. Grasso et al.
CANCER DISCOVERY (2018)
Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images
Joel Saltz et al.
CELL REPORTS (2018)
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Min Hwan Kim et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Rebekka Weber et al.
FRONTIERS IN IMMUNOLOGY (2018)
PD-L1 expression is regulated by both DNA methylation and NF-kappa B during EMT signaling in non-small cell lung carcinoma
A. Asgarova et al.
ONCOIMMUNOLOGY (2018)
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Tammy Linlin Song et al.
BLOOD (2018)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong-Ho Cha et al.
MOLECULAR CELL (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Li Wang et al.
NATURE COMMUNICATIONS (2018)
Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF beta Inhibitor Sequencing in Melanoma
Fei Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma
Xiao-Yu Chen et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2018)
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Jung-Mao Hsu et al.
CANCER RESEARCH (2018)
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
Aniruddha Chatterjee et al.
ISCIENCE (2018)
Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Julie George et al.
CLINICAL CANCER RESEARCH (2017)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
S. Murakami et al.
ONCOGENE (2017)
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Matthew A. Coelho et al.
IMMUNITY (2017)
MicroRNA-155 induction via TNF- and IFN- suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells
Daniel Yee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C. Kao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs
A. R. Pyzer et al.
LEUKEMIA (2017)
MYC expression correlates with PD-L1 expression in non-small cell lung cancer
Eun Young Kim et al.
LUNG CANCER (2017)
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma
Carlos A. Morales-Betanzos et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Riccardo Mezzadra et al.
NATURE (2017)
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Marian L. Burr et al.
NATURE (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
Joseph P. Antonios et al.
NEURO-ONCOLOGY (2017)
Helicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer Cells
Gengchen Xie et al.
PLOS ONE (2017)
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells
Victor Prima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1
Michele Cioffi et al.
ONCOTARGET (2017)
miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression
Susheng Miao et al.
ONCOTARGET (2017)
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Valentina Audrito et al.
ONCOTARGET (2017)
YAP regulates PD-L1 expression in human NSCLC cells
Jinbai Miao et al.
ONCOTARGET (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Takuro Noguchi et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
Muhammad Zaeem Noman et al.
ONCOIMMUNOLOGY (2017)
Role of microRNA-33a in regulating the expression of PD-1 in lung adenocarcinoma
Laura Boldrini et al.
CANCER CELL INTERNATIONAL (2017)
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcilloma
Byung Soo Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Ricardo E. Vilain et al.
CLINICAL CANCER RESEARCH (2017)
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Alejandro Jimenez-Sanchez et al.
CELL (2017)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger et al.
CLINICAL CANCER RESEARCH (2017)
miR-142-5p regulates tumor cell PD-Ll expression and enhances anti-tumor immunity
Long Jia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma
Satoshi Tsutsumi et al.
CANCER SCIENCE (2017)
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer
Heath D. Skinner et al.
CLINICAL CANCER RESEARCH (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α
Genevieve Hartley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1
Wei-Jun Chen et al.
ATHEROSCLEROSIS (2016)
Deubiquitination and Stabilization of PD-L1 by CSN5
Seung-Oe Lim et al.
CANCER CELL (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Yanyan Lou et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore et al.
CLINICAL CANCER RESEARCH (2016)
Pan-Cancer Analysis of Copy Number Changes in Programmed Death-Ligand 1 (PD-L1, CD274) - Associations with Gene Expression, Mutational Load, and Survival
Jan Budczies et al.
GENES CHROMOSOMES & CANCER (2016)
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Asim Saha et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
What does PD-L1 positive or negative mean?
Antoni Ribas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Chia-Wei Li et al.
NATURE COMMUNICATIONS (2016)
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu et al.
NATURE COMMUNICATIONS (2016)
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Pei-Ling Chen et al.
CANCER DISCOVERY (2016)
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
Chan-Young Ock et al.
ONCOTARGET (2016)
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Lian Zhao et al.
ONCOTARGET (2016)
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells
Xin Liu et al.
SCIENTIFIC REPORTS (2016)
Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
Vishwajith Sridharan et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Randy F. Sweis et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Sonja Kleffel et al.
CELL (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
Michael T. Barrett et al.
ONCOTARGET (2015)
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Jie Zhang et al.
THORACIC CANCER (2015)
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
Kavitha Gowrishankar et al.
PLOS ONE (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
MiR-20b,-21, and-130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer
Jianjie Zhu et al.
HUMAN IMMUNOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151
Stuart J. Gallagher et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Judith Mueller et al.
NATURE COMMUNICATIONS (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Tobias Bald et al.
CANCER DISCOVERY (2014)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
Weipeng Wang et al.
HUMAN GENETICS (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin-dependent manner
Alexander Scholz et al.
BLOOD (2011)
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Roberta Mazzieri et al.
CANCER CELL (2011)
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola et al.
CLINICAL CANCER RESEARCH (2011)
B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival
Vesna Pulko et al.
JOURNAL OF IMMUNOLOGY (2011)
Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
Seth B. Coffelt et al.
JOURNAL OF IMMUNOLOGY (2011)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes
Ai-Yu Gong et al.
JOURNAL OF IMMUNOLOGY (2009)
Cutting Edge: IFN-γ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development
Ilona Kryczek et al.
JOURNAL OF IMMUNOLOGY (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Epithelial-mesenchymal transitions:: Twist in development and metastasis
YB Kang et al.
CELL (2004)
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via R-T interactions
PA Taylor et al.
JOURNAL OF IMMUNOLOGY (2004)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation:: relevance for the immune modulatory effect in multiple sclerosis
B Schreiner et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
JA Brown et al.
JOURNAL OF IMMUNOLOGY (2003)
Endothelial expression of PD-L1 and PD-L2 down-regulates CD8(+) T cell activation and cytolysis
N Rodig et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis
MM Mazanet et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
